TopiVert Limited
United Kingdom

TopiVert Limited is a drug discovery and development company dedicated to improving patient care in inflammatory diseases of the gut and the eye.

The company was founded in 2011 with intellectual property and know-how from RespiVert, a company acquired by Johnson & Johnson in 2010. The company is developing Narrow Spectrum Kinase Inhibitors for the topical treatment of inflammatory diseases in the gut and the eye.

Existing treatments for both these conditions are generally not satisfactory for patients and TopiVert aims to offer NSKIs that have an equivalent level of efficacy to steroids, yet without the negative side effects and potential resistance.

The market for inflammatory bowel disease in the United States, Japan and Europe is expected to reach $5.9 billion by 2019, and the global market for uveitis to reach $1.6 billion by 2017.

Status: Active